Back to Agenda
The FDA's Commitment to Patient-Centric Research: Key Themes from Decentralized Trial Draft Guidance
Session Chair(s)
Rasika Kalamegham, PHD
Head, US Regulatory Policy, Genentech, A Member of the Roche Group, United States
This interactive forum will explore the key themes and industry feedback from the decentralized trials alliance members’ response to the FDA draft guidance on decentralized clinical trials.
Learning Objective : Examine how the FDA draft guidance reflects a commitment to patient-centric decentralized clinical trials; Identify key themes and industry feedback provided in the alliance's response to the draft guidance; Discuss the next steps needed to enable adoption of decentralized trials under the draft framework.
Speaker(s)
Collaboration Perspective
VP, Programs and Initiatives, Digital Trials and Research Alliance, United States
FDA Perspective
Vice President, Regulatory Policy, BridgeBio, United States
Industry Perspective
Director, Regulatory Policy, North America, Johnson & Johnson, United States
Have an account?